Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study

NCT02251821 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT02251821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02251821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
October 20, 2014
Completion date
January 22, 2026
Enrollment
61 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary myelofibrosis, secondary myelofibrosis